Cytokinetics’ Cardio Bet Pays Off with Amgen Option Exercise
Cytokinetics Inc.’s decision to scrap its internal oncology programs and focus on heart failure drug CK-1827452 is looking pretty smart now that partner Amgen Inc. exercised its option on the drug, triggering a $50 million payment to Cytokinetics. Amgen will cover all future expenses, including two [...]